[Dual 5-alpha reductase inhibitors in BPH (benign prostatic hyperplasia). Already after 1 month prostate shrinks].
D058891:5-alpha Reductase Inhibitors; D001378:Azasteroids / Q000008:administration & dosage / Q000627:therapeutic use*; D017326:Clinical Trials, Phase III as Topic; D000068538:Dutasteride; D004791:Enzyme Inhibitors / Q000627:therapeutic use*; D018120:Finasteride / Q000627:therapeutic use; D006801:Humans; D007231:Infant, Newborn; D008297:Male; D010919:Placebos; D011467:Prostate / Q000473:pathology; D017430:Prostate-Specific Antigen / Q000097:blood; D011470:Prostatic Hyperplasia / Q000150:complications / Q000000981:diagnostic imaging / Q000188:drug therapy*; D011471:Prostatic Neoplasms / Q000209:etiology; D012307:Risk Factors; D013739:Testosterone / Q000097:blood; D013997:Time Factors; D014463:Ultrasonography
D058891:5-alpha Reductase Inhibitors; D001378:Azasteroids; D004791:Enzyme Inhibitors; D010919:Placebos; D013739:Testosterone; D018120:Finasteride; D017430:Prostate-Specific Antigen; D000068538:Dutasteride